New cream offers hope for rare skin cancer patients
NCT ID NCT06698822
Summary
This study is testing whether a cream containing the drug tofacitinib can safely and effectively treat early-stage cutaneous T-cell lymphoma, a rare type of skin cancer. The trial will involve 20 adults with early-stage disease who have at least two skin lesions that haven't responded to previous treatment. Participants will apply the cream to affected areas for 12 weeks, with some continuing for up to a year to see how well it controls the cancer and improves symptoms like itching.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.